Key Highlights
● Second-quarter Revenue rose 17.2% to $707.3 million, with diluted EPS of $4.25.
● Net new Business awards climbed 28.2% to $795.7 million, lifting book-to-bill to 1.13x.
● The company holds $502.7 million in cash and carries no Debt on its balance sheet.
● Medpace reports third-quarter 2026 results after market close on October 21, 2026.
Medpace Holdings, Inc. (NASDAQ:MEDP), a clinical research organisation serving biotechnology and pharmaceutical sponsors, is scheduled to report third-quarter 2026 results after the market close on Wednesday, October 21, 2026, with a conference call the following morning. Ahead of that update, interest-rate exposure offers a useful lens. The company guided to roughly $21.1 million of 2026 interest income and held $502.7 million of cash at June 30, while its Balance Sheet in the July release showed no debt line item. Rate moves may therefore matter through Investment income and client funding conditions more than through borrowing costs.
Latest Company Context
In the second quarter, reported July 22, 2026, revenue rose 17.2% to $707.3 million. GAAP Net Income was $121.4 million and diluted EPS was $4.25, compared with $3.10 a year earlier. Net new business awards rose 28.2% to $795.7 million, producing a net book-to-bill of 1.13x, and Backlog ended June at $3,014.2 million, up 4.9%. Management guidance for full-year 2026 calls for revenue of $2.805 billion to $2.885 billion, GAAP net income of $494.0 million to $514.0 million, diluted EPS of $17.25 to $17.95, EBITDA of $618.0 million to $642.0 million and a tax rate of 19.0% to 19.5%. Six-month revenue was $1,413.9 million, up 21.7%, with diluted EPS of $8.53. Second-quarter Operating Cash Flow was $162.0 million, and non-GAAP EBITDA was $153.4 million, a 21.7% margin.
Key Business and index Drivers
Several rate-related drivers are worth separating. Interest income depends on cash balances and yields, and the company repurchased 705,616 shares for $294.7 million in the second quarter, with $527.0 million of authorisation remaining. Management said its guidance excludes repurchases after June 30, so further Buybacks could change the cash base. Separately, as general market context rather than company commentary, borrowing costs and equity-market conditions can influence how readily early-stage biotechnology sponsors raise capital, which may in turn affect new awards. Backlog conversion into revenue remains the central operating driver. No major US index membership could be verified. Interest income is modest relative to operating earnings: $21.1 million compares with guided GAAP net income of $494.0 million to $514.0 million, so direct Earnings sensitivity to rate changes may be limited.
What Investors Should Watch
The October 21 release is the key catalyst. Investors may watch net new business and book-to-bill against the 1.13x recorded in the second quarter, backlog growth, and whether full-year guidance is maintained, raised or narrowed. Interest income relative to the $21.1 million estimate may show how cash deployment and yields are interacting. The cash balance after any further repurchases, the tax rate and cancellation trends are additional items that may be informative. The employee base of about 6,500 across 46 countries as of June 30, 2026 also frames capacity, and updates on hiring or utilisation may help investors judge whether revenue growth can be sustained at current margins.
A Growth Story With a Rate-Sensitive Side Note
Medpace enters its next report with strong second-quarter growth, a large and growing backlog and a debt-free balance sheet that leaves earnings partly linked to interest income. That linkage is a secondary Factor beside awards and execution, yet it adds a rate-sensitive element to an otherwise operations-driven story. The coming results may clarify how bookings, cash returns and guidance fit together.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...